Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29183504 | 0.87 | — | — | |
| Water SCHEMBL28036631 | 0.87 | — | — | |
| Water SCHEMBL29365212 | 0.82 | — | — | |
| Water SCHEMBL30733179 | 0.82 | — | — | |
| Lithium Ion SCHEMBL22241 | 0.82 | — | — | |
| Lithium Ion SCHEMBL278068 | 0.82 | — | — | |
| Lithium Ion SCHEMBL20603256 | 0.82 | — | — | |
| Water SCHEMBL2492718 | 0.82 | — | — | |
| Lithium Ion SCHEMBL7128298 | 0.82 | — | — | |
| Water SCHEMBL27464336 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105884833-B | Preparation method and antitumor activity of novel ruthenium complex containing 4, 4 '-dibromo-2, 2' -bipyridyl | 江南大学 | 2020-05-08 | — | — | CN | claimed |
| CN-105884833-A | Preparation method and antineoplastic activity of novel ruthenium complex containing 4,4'-dibromo-2,2'-dipyridyl | 江南大学 | 2016-08-24 | — | — | CN | claimed |
| US-20250188040-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS INC | 2025-06-12 | — | — | US | disclosed |
| EP-4551555-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | Vividion Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119677716-A | Pharmaceutical compositions comprising WRN helicase inhibitors | 维维迪恩医疗公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12187685-B2 | Pharmaceutical compositions comprising WRN helicase inhibitors | VIVIDION THERAPEUTICS, INC. | 2025-01-07 | — | — | US | disclosed |
| EP-4434982-A1 | (S)-2-(2-METHYLAZETIDIN-1-YL)PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | LG Chem, Ltd. (KR) | 2024-09-25 | — | — | EP | disclosed |
| CN-118414332-A | (S) -2- (2-methylazetidin-1-yl) pyrimidine derivatives and pharmaceutical compositions containing the same | 株式会社LG化学 | 2024-07-30 | — | — | CN | disclosed |
| US-20240140915-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-05-02 | — | — | US | disclosed |
| US-20240067612-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| WO-2024010782-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS | VIVIDION THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| CN-111247101-A | Nickel composite oxide and method for producing lithium nickel composite oxide | 住友金属矿山株式会社 | 2020-06-05 | — | — | CN | disclosed |
| CN-105884833-B | Preparation method and antitumor activity of novel ruthenium complex containing 4, 4 '-dibromo-2, 2' -bipyridyl | 江南大学 | 2020-05-08 | — | — | CN | disclosed |
| CN-104321060-B | Alpha-amino boronic acid derivative, selective immunoproteasome inhibitor | 阿雷斯贸易股份有限公司 | 2018-08-07 | — | — | CN | disclosed |
| US-20170187057-A1 | HYDROGEN GENERATOR AND FUEL CELL SYSTEM AND METHOD | ARIZONA BOARD OF REGENT ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-06-29 | — | — | US | disclosed |
| CN-105884833-A | Preparation method and antineoplastic activity of novel ruthenium complex containing 4,4'-dibromo-2,2'-dipyridyl | 江南大学 | 2016-08-24 | — | — | CN | disclosed |
| WO-2007058482-A1 | NOVEL INHIBITORS OF PROTEIN KINASE | LG LIFE SCIENCES, LTD. (KR) | 2007-05-24 | — | — | WO | disclosed |
| CN-1487120-A | Electrolytic process of preparing lithium hydroxide from lithium carbonate | 新疆大学 | 2004-04-07 | — | — | CN | disclosed |
| US-6344294-B1 | DISSOLVING COMPOUNDS OF LITHIUM, NICKEL AND OPTIONALLY ANOTHER METAL(M) IN A BUFFER SOLUTION CONTAINING LITHIUM IONS; ADDING OXALIC ACID TO FORM A PRECIPITATE OF OXALATES; CALCINING THE PRECIPITATE TO PRODUCE LINI(1-X)MXO2 | SHARP KABUSHIKI KAISHA (JP) | 2002-02-05 | — | — | US | disclosed |
| EP-0686628-A2 | Prostaglandin F esters | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-12-13 | — | — | EP | disclosed |